O	O	O	0	8	Blockade	Blockade	B-NP	NN	O	9	SUB	O
O	O	O	9	11	of	of	B-PP	IN	O	1	NMOD	O
O	O	O	12	13	T	T	B-NP	NN	B-cell_type	6	NMOD	B-cell_type
O	O	O	13	14	-	-	I-NP	HYPH	I-cell_type	6	NMOD	I-cell_type
O	O	O	14	18	cell	cell	I-NP	NN	I-cell_type	6	NMOD	I-cell_type
O	O	O	19	29	activation	activation	I-NP	NN	O	2	PMOD	O
O	O	O	30	32	by	by	B-PP	IN	O	1	NMOD	O
O	O	O	33	49	dithiocarbamates	dithiocarbamate	B-NP	NNS	O	7	PMOD	O
O	O	O	50	58	involves	involve	B-VP	VBZ	O	0	ROOT	O
O	O	O	59	64	novel	novel	B-NP	JJ	O	11	NMOD	O
O	O	O	65	75	mechanisms	mechanism	I-NP	NNS	O	9	OBJ	O
O	O	O	76	78	of	of	B-PP	IN	O	11	NMOD	O
O	O	O	79	89	inhibition	inhibition	B-NP	NN	O	12	PMOD	O
O	O	O	90	92	of	of	B-PP	IN	O	13	NMOD	O
O	O	O	93	100	nuclear	nuclear	B-NP	JJ	B-protein	14	PMOD	B-protein
O	O	O	101	107	factor	factor	I-NP	NN	I-protein	15	NMOD	I-protein
O	O	O	108	110	of	of	B-PP	IN	I-protein	16	NMOD	I-protein
O	O	O	111	120	activated	activate	B-NP	VBN	I-protein	20	NMOD	I-protein
O	O	O	121	122	T	T	I-NP	NN	I-protein	20	NMOD	I-protein
O	O	O	123	128	cells	cell	I-NP	NNS	I-protein	17	PMOD	I-protein
O	O	O	128	129	.	.	O	.	O	9	P	O

O	O	O	131	147	Dithiocarbamates	Dithiocarbamate	B-NP	NNS	O	5	SUB	O
O	O	O	148	149	(	(	O	(	O	4	DEP	O
O	O	O	149	153	DTCs	DTC	B-NP	NNS	O	4	DEP	O
O	O	O	153	154	)	)	O	)	O	1	NMOD	O
O	O	O	155	159	have	have	B-VP	VBP	O	0	ROOT	O
O	O	O	160	168	recently	recently	I-VP	RB	O	5	VMOD	O
O	O	O	169	173	been	be	I-VP	VBN	O	5	VC	O
O	O	O	174	182	reported	report	I-VP	VBN	O	7	VC	O
O	O	O	183	185	as	as	B-PP	IN	O	8	VMOD	O
O	O	O	186	194	powerful	powerful	B-NP	JJ	O	11	NMOD	O
O	O	O	195	205	inhibitors	inhibitor	I-NP	NNS	O	9	PMOD	O
O	O	O	206	208	of	of	B-PP	IN	O	11	NMOD	O
T11	B-Entity	B-Entity	209	211	NF	NF	B-NP	NN	B-protein	15	NMOD	B-protein
T11	I-Entity	I-Entity	211	212	-	-	B-NP	HYPH	I-protein	15	NMOD	I-protein
T11	I-Entity	I-Entity	212	218	kappaB	kappaB	I-NP	NN	I-protein	16	NMOD	I-protein
O	O	O	219	229	activation	activation	I-NP	NN	O	12	PMOD	O
O	O	O	230	232	in	in	B-PP	IN	O	8	VMOD	O
O	O	O	233	234	a	a	B-NP	DT	O	19	NMOD	O
O	O	O	235	241	number	number	I-NP	NN	O	17	PMOD	O
O	O	O	242	244	of	of	B-PP	IN	O	19	NMOD	O
O	O	O	245	249	cell	cell	B-NP	NN	O	22	NMOD	O
O	O	O	250	255	types	type	I-NP	NNS	O	20	PMOD	O
O	O	O	255	256	.	.	O	.	O	5	P	O

O	O	O	257	262	Given	Give	B-PP	VBN	O	23	VMOD	O
O	O	O	263	266	the	the	B-NP	DT	O	3	NMOD	O
O	O	O	267	271	role	role	I-NP	NN	O	1	PMOD	O
O	O	O	272	274	of	of	B-PP	IN	O	3	NMOD	O
O	O	O	275	279	this	this	B-NP	DT	O	7	NMOD	O
O	O	O	280	293	transcription	transcription	I-NP	NN	B-protein	7	NMOD	B-protein
O	O	O	294	300	factor	factor	I-NP	NN	I-protein	4	PMOD	I-protein
O	O	O	301	303	in	in	B-PP	IN	O	3	NMOD	O
O	O	O	304	307	the	the	B-NP	DT	O	10	NMOD	O
O	O	O	308	318	regulation	regulation	I-NP	NN	O	8	PMOD	O
O	O	O	319	321	of	of	B-PP	IN	O	10	NMOD	O
O	O	O	322	326	gene	gene	B-NP	NN	O	13	NMOD	O
O	O	O	327	337	expression	expression	I-NP	NN	O	11	PMOD	O
O	O	O	338	340	in	in	B-PP	IN	O	10	NMOD	O
O	O	O	341	344	the	the	B-NP	DT	O	17	NMOD	O
O	O	O	345	357	inflammatory	inflammatory	I-NP	JJ	O	17	NMOD	O
O	O	O	358	366	response	response	I-NP	NN	O	14	PMOD	O
O	O	O	366	367	,	,	O	,	O	23	P	O
T12	B-Entity	B-Entity	368	370	NF	NF	B-NP	NN	B-protein	22	NMOD	B-protein
T12	I-Entity	I-Entity	370	371	-	-	B-NP	HYPH	I-protein	22	NMOD	I-protein
T12	I-Entity	I-Entity	371	377	kappaB	kappaB	I-NP	NN	I-protein	22	NMOD	I-protein
O	O	O	378	388	inhibitors	inhibitor	I-NP	NNS	O	23	SUB	O
O	O	O	389	393	have	have	B-VP	VBP	O	0	ROOT	O
O	O	O	394	398	been	be	I-VP	VBN	O	23	VC	O
O	O	O	399	408	suggested	suggest	I-VP	VBN	O	24	VC	O
O	O	O	409	411	as	as	B-PP	IN	O	25	VMOD	O
O	O	O	412	421	potential	potential	B-NP	JJ	O	29	NMOD	O
O	O	O	422	433	therapeutic	therapeutic	I-NP	JJ	O	29	NMOD	O
O	O	O	434	439	drugs	drug	I-NP	NNS	O	26	PMOD	O
O	O	O	440	443	for	for	B-PP	IN	O	29	NMOD	O
O	O	O	444	456	inflammatory	inflammatory	B-NP	JJ	O	32	NMOD	O
O	O	O	457	465	diseases	disease	I-NP	NNS	O	30	PMOD	O
O	O	O	465	466	.	.	O	.	O	23	P	O

O	O	O	467	469	We	We	B-NP	PRP	O	2	SUB	O
O	O	O	470	474	show	show	B-VP	VBP	O	0	ROOT	O
O	O	O	475	479	here	here	B-ADVP	RB	O	2	VMOD	O
O	O	O	480	484	that	that	B-SBAR	IN	O	2	VMOD	O
O	O	O	485	489	DTCs	DTC	B-NP	NNS	O	6	SUB	O
O	O	O	490	499	inhibited	inhibit	B-VP	VBD	O	4	SBAR	O
O	O	O	500	504	both	both	O	CC	O	18	NMOD	O
T1	B-Protein	B-Protein	505	516	interleukin	interleukin	B-NP	NN	B-protein	15	NMOD	B-protein
T1	I-Protein	I-Protein	517	518	2	2	I-NP	CD	I-protein	8	NMOD	I-protein
O	O	O	519	520	(	(	O	(	O	14	DEP	O
T2	B-Protein	B-Protein	520	522	IL	IL	B-NP	NN	B-protein	14	DEP	B-protein
T2	I-Protein	I-Protein	522	523	-	-	O	HYPH	I-protein	11	NMOD	I-protein
T2	I-Protein	I-Protein	523	524	2	2	O	CD	I-protein	11	NMOD	I-protein
O	O	O	524	525	)	)	O	)	O	8	NMOD	O
O	O	O	526	535	synthesis	synthesis	B-NP	NN	O	18	NMOD	O
O	O	O	536	539	and	and	O	CC	O	18	NMOD	O
O	O	O	540	548	membrane	membrane	B-NP	NN	O	18	NMOD	O
O	O	O	549	559	expression	expression	I-NP	NN	O	6	OBJ	O
O	O	O	560	562	of	of	B-PP	IN	O	18	NMOD	O
O	O	O	563	571	antigens	antigen	B-NP	NNS	B-protein	19	PMOD	B-protein
O	O	O	572	577	which	which	B-NP	WDT	O	20	NMOD	O
O	O	O	578	581	are	be	B-VP	VBP	O	21	SBAR	O
O	O	O	582	589	induced	induce	I-VP	VBN	O	22	VC	O
O	O	O	590	596	during	during	B-PP	IN	O	23	VMOD	O
O	O	O	597	598	T	T	B-NP	NN	O	28	NMOD	O
O	O	O	598	599	-	-	I-NP	HYPH	O	28	NMOD	O
O	O	O	599	603	cell	cell	I-NP	NN	O	28	NMOD	O
O	O	O	604	614	activation	activation	I-NP	NN	O	24	PMOD	O
O	O	O	614	615	.	.	O	.	O	2	P	O

O	O	O	616	620	This	This	B-NP	DT	O	2	NMOD	O
O	O	O	621	631	inhibition	inhibition	I-NP	NN	O	19	SUB	O
O	O	O	631	632	,	,	O	,	O	2	P	O
O	O	O	633	638	which	which	B-NP	WDT	O	2	NMOD	O
O	O	O	639	647	occurred	occur	B-VP	VBD	O	4	SBAR	O
O	O	O	648	652	with	with	B-PP	IN	O	5	VMOD	O
O	O	O	653	654	a	a	B-NP	DT	O	9	NMOD	O
O	O	O	655	663	parallel	parallel	I-NP	JJ	O	9	NMOD	O
O	O	O	664	674	activation	activation	I-NP	NN	O	6	PMOD	O
O	O	O	675	677	of	of	B-PP	IN	O	9	NMOD	O
T3	B-Protein	B-Protein	678	679	c	c	B-NP	NN	O	13	NMOD	O
T3	I-Protein	I-Protein	679	680	-	-	B-NP	HYPH	O	13	P	O
T3	I-Protein	I-Protein	680	683	Jun	Jun	I-NP	NN	B-protein	10	PMOD	B-protein
O	O	O	684	699	transactivating	transactivate	B-VP	VBG	O	9	NMOD	O
O	O	O	700	709	functions	function	B-NP	NNS	O	17	NMOD	O
O	O	O	710	713	and	and	O	CC	O	17	NMOD	O
O	O	O	714	724	expression	expression	B-NP	NN	O	14	OBJ	O
O	O	O	724	725	,	,	O	,	O	2	P	O
O	O	O	726	729	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	730	739	reflected	reflect	I-VP	VBN	O	19	VC	O
O	O	O	740	742	by	by	B-PP	IN	O	20	VMOD	O
O	O	O	743	755	transfection	transfection	B-NP	NN	O	23	NMOD	O
O	O	O	756	767	experiments	experiment	I-NP	NNS	O	21	PMOD	O
O	O	O	768	770	at	at	B-PP	IN	O	20	VMOD	O
O	O	O	771	774	the	the	B-NP	DT	O	30	NMOD	O
T4	B-Protein	B-Protein	775	777	IL	IL	I-NP	NN	B-DNA	29	NMOD	B-DNA
T4	I-Protein	I-Protein	777	778	-	-	B-NP	HYPH	I-DNA	29	NMOD	I-DNA
T4	I-Protein	I-Protein	778	779	2	2	I-NP	CD	I-DNA	29	NMOD	I-DNA
T13	B-Entity	B-Entity	780	788	promoter	promoter	I-NP	NN	I-DNA	30	NMOD	I-DNA
O	O	O	789	794	level	level	I-NP	NN	O	24	PMOD	O
O	O	O	794	795	,	,	O	,	O	19	P	O
O	O	O	796	799	and	and	O	CC	O	19	VMOD	O
O	O	O	800	808	involved	involve	B-VP	VBD	O	19	VMOD	O
O	O	O	809	812	not	not	B-CONJP	RB	O	48	NMOD	O
O	O	O	813	817	only	only	I-CONJP	RB	O	34	DEP	O
O	O	O	818	821	the	the	B-NP	DT	O	37	NMOD	O
O	O	O	822	832	inhibition	inhibition	I-NP	NN	O	45	NMOD	O
O	O	O	833	835	of	of	B-PP	IN	O	37	NMOD	O
T14	B-Entity	B-Entity	836	838	NF	NF	B-NP	NN	B-protein	41	NMOD	B-protein
T14	I-Entity	I-Entity	838	839	-	-	B-NP	HYPH	I-protein	41	NMOD	I-protein
T14	I-Entity	I-Entity	839	845	kappaB	kappaB	I-NP	NN	I-protein	38	PMOD	I-protein
O	O	O	845	846	-	-	O	HYPH	O	45	NMOD	O
O	O	O	846	852	driven	drive	B-NP	VBN	O	45	NMOD	O
T15	B-Entity	B-Entity	853	861	reporter	reporter	I-NP	NN	O	45	NMOD	O
O	O	O	862	872	activation	activation	I-NP	NN	O	48	NMOD	O
O	O	O	873	876	but	but	B-CONJP	CC	O	48	NMOD	O
O	O	O	877	881	also	also	I-CONJP	RB	O	46	DEP	O
O	O	O	882	886	that	that	B-NP	DT	O	33	OBJ	O
O	O	O	887	889	of	of	B-PP	IN	O	48	NMOD	O
O	O	O	890	897	nuclear	nuclear	B-NP	JJ	B-protein	55	NMOD	B-protein
O	O	O	898	904	factor	factor	I-NP	NN	I-protein	55	NMOD	I-protein
O	O	O	905	907	of	of	B-PP	IN	I-protein	55	NMOD	I-protein
O	O	O	908	917	activated	activate	B-NP	VBN	I-protein	55	NMOD	I-protein
O	O	O	918	919	T	T	I-NP	NN	I-protein	55	NMOD	I-protein
O	O	O	920	925	cells	cell	I-NP	NNS	I-protein	49	PMOD	I-protein
O	O	O	926	927	(	(	O	(	O	58	DEP	O
O	O	O	927	931	NFAT	NFAT	B-NP	NN	B-protein	58	DEP	B-protein
O	O	O	931	932	)	)	O	)	O	55	NMOD	O
O	O	O	932	933	.	.	O	.	O	19	P	O

O	O	O	934	945	Accordingly	Accordingly	B-ADVP	RB	O	10	VMOD	O
O	O	O	945	946	,	,	O	,	O	10	P	O
O	O	O	947	962	electrophoretic	electrophoretic	B-NP	JJ	O	6	NMOD	O
O	O	O	963	971	mobility	mobility	I-NP	NN	O	6	NMOD	O
O	O	O	972	977	shift	shift	I-NP	NN	O	6	NMOD	O
O	O	O	978	984	assays	assay	I-NP	NNS	O	10	SUB	O
O	O	O	985	986	(	(	O	(	O	9	DEP	O
O	O	O	986	991	EMSAs	EMSA	B-NP	NNS	O	9	DEP	O
O	O	O	991	992	)	)	O	)	O	6	NMOD	O
O	O	O	993	1002	indicated	indicate	B-VP	VBD	O	0	ROOT	O
O	O	O	1003	1007	that	that	B-SBAR	IN	O	10	VMOD	O
O	O	O	1008	1019	pyrrolidine	pyrrolidine	B-NP	NN	O	13	NMOD	O
O	O	O	1020	1023	DTC	DTC	I-NP	NN	O	17	SUB	O
O	O	O	1024	1025	(	(	O	(	O	16	DEP	O
O	O	O	1025	1029	PDTC	PDTC	B-NP	NN	O	16	DEP	O
O	O	O	1029	1030	)	)	O	)	O	13	NMOD	O
O	O	O	1031	1040	prevented	prevent	B-VP	VBD	O	27	VMOD	O
T16	B-Entity	B-Entity	1041	1043	NF	NF	B-NP	NN	B-protein	20	NMOD	B-protein
T16	I-Entity	I-Entity	1043	1044	-	-	B-NP	HYPH	I-protein	20	NMOD	I-protein
T16	I-Entity	I-Entity	1044	1050	kappaB	kappaB	I-NP	NN	I-protein	17	OBJ	I-protein
O	O	O	1050	1051	,	,	O	,	O	27	P	O
O	O	O	1052	1055	and	and	O	CC	O	27	NMOD	O
O	O	O	1056	1060	NFAT	NFAT	B-NP	NN	B-protein	27	NMOD	B-protein
T17	B-Entity	B-Entity	1061	1064	DNA	DNA	I-NP	NN	O	27	NMOD	O
O	O	O	1064	1065	-	-	B-NP	HYPH	O	27	NMOD	O
O	O	O	1065	1072	binding	binding	I-NP	NN	O	27	NMOD	O
O	O	O	1073	1081	activity	activity	I-NP	NN	O	52	SUB	O
O	O	O	1082	1084	in	in	B-PP	IN	O	27	NMOD	O
O	O	O	1085	1086	T	T	B-NP	NN	B-cell_type	30	NMOD	B-cell_type
O	O	O	1087	1092	cells	cell	I-NP	NNS	I-cell_type	28	PMOD	I-cell_type
O	O	O	1093	1103	stimulated	stimulate	B-VP	VBN	O	30	NMOD	O
O	O	O	1104	1108	with	with	B-PP	IN	O	31	VMOD	O
O	O	O	1109	1115	either	either	O	CC	O	40	NMOD	O
O	O	O	1116	1123	phorbol	phorbol	B-NP	NN	O	36	NMOD	O
O	O	O	1124	1133	myristate	myristate	I-NP	NN	O	36	NMOD	O
O	O	O	1134	1141	acetate	acetate	I-NP	NN	O	38	NMOD	O
O	O	O	1142	1146	plus	plus	O	CC	O	38	NMOD	O
O	O	O	1147	1156	ionophore	ionophore	B-NP	NN	O	40	NMOD	O
O	O	O	1157	1159	or	or	I-NP	CC	O	40	NMOD	O
O	O	O	1160	1170	antibodies	antibody	I-NP	NNS	O	32	PMOD	O
O	O	O	1171	1178	against	against	B-PP	IN	O	40	NMOD	O
O	O	O	1179	1182	the	the	B-NP	DT	O	49	NMOD	O
T18	B-Entity	B-Entity	1183	1186	CD3	CD3	I-NP	NN	B-protein	44	NMOD	B-protein
T18	I-Entity	I-Entity	1186	1187	-	-	I-NP	HYPH	O	49	NMOD	O
T18	I-Entity	I-Entity	1187	1188	T	T	I-NP	NN	B-protein	49	NMOD	B-protein
T18	I-Entity	I-Entity	1188	1189	-	-	I-NP	HYPH	I-protein	49	NMOD	I-protein
T18	I-Entity	I-Entity	1189	1193	cell	cell	I-NP	NN	I-protein	49	NMOD	I-protein
T18	I-Entity	I-Entity	1194	1202	receptor	receptor	I-NP	NN	I-protein	49	NMOD	I-protein
T18	I-Entity	I-Entity	1203	1210	complex	complex	I-NP	NN	I-protein	41	PMOD	I-protein
O	O	O	1211	1214	and	and	O	CC	O	27	VMOD	O
O	O	O	1215	1229	simultaneously	simultaneously	B-VP	RB	O	52	VMOD	O
O	O	O	1230	1239	activated	activate	I-VP	VBD	O	11	SBAR	O
O	O	O	1240	1243	the	the	B-NP	DT	O	54	NMOD	O
O	O	O	1244	1251	binding	binding	I-NP	NN	O	52	OBJ	O
O	O	O	1252	1254	of	of	B-PP	IN	O	54	NMOD	O
T19	B-Entity	B-Entity	1255	1257	AP	AP	B-NP	NN	B-protein	57	NMOD	B-protein
T19	I-Entity	I-Entity	1257	1258	-	-	B-NP	HYPH	I-protein	55	PMOD	I-protein
T19	I-Entity	I-Entity	1258	1259	1	1	I-NP	CD	I-protein	57	NMOD	I-protein
O	O	O	1259	1260	.	.	O	.	O	10	P	O

O	O	O	1261	1272	Furthermore	Furthermore	B-ADVP	RB	O	5	VMOD	O
O	O	O	1272	1273	,	,	O	,	O	5	P	O
O	O	O	1274	1278	PDTC	PDTC	B-NP	NN	O	5	SUB	O
O	O	O	1279	1293	differentially	differentially	B-ADVP	RB	O	5	VMOD	O
O	O	O	1294	1302	targeted	target	B-VP	VBD	O	0	ROOT	O
O	O	O	1303	1307	both	both	O	CC	O	11	NMOD	O
T5	B-Protein	B-Protein	1308	1313	NFATp	NFATp	B-NP	NN	B-protein	11	NMOD	B-protein
O	O	O	1314	1317	and	and	O	CC	O	11	NMOD	O
O	O	O	1318	1323	NFATc	NFATc	B-NP	NN	B-protein	11	NMOD	B-protein
O	O	O	1324	1330	family	family	I-NP	NN	I-protein	11	NMOD	I-protein
O	O	O	1331	1338	members	member	I-NP	NNS	I-protein	5	OBJ	I-protein
O	O	O	1338	1339	,	,	O	,	O	5	P	O
O	O	O	1340	1350	inhibiting	inhibit	B-VP	VBG	O	5	VMOD	O
O	O	O	1351	1354	the	the	B-NP	DT	O	16	NMOD	O
O	O	O	1355	1370	transactivation	transactivation	I-NP	NN	O	16	NMOD	O
O	O	O	1371	1380	functions	function	I-NP	NNS	O	21	NMOD	O
O	O	O	1381	1383	of	of	B-PP	IN	O	16	NMOD	O
T6	B-Protein	B-Protein	1384	1389	NFATp	NFATp	B-NP	NN	B-protein	17	PMOD	B-protein
O	O	O	1390	1393	and	and	O	CC	O	21	NMOD	O
O	O	O	1394	1398	mRNA	mRNA	B-NP	NN	O	21	NMOD	O
O	O	O	1399	1408	induction	induction	I-NP	NN	O	13	OBJ	O
O	O	O	1409	1411	of	of	B-PP	IN	O	21	NMOD	O
O	O	O	1412	1417	NFATc	NFATc	B-NP	NN	B-protein	22	PMOD	B-protein
O	O	O	1417	1418	.	.	O	.	O	5	P	O

O	O	O	1419	1429	Strikingly	Strikingly	B-ADVP	RB	O	8	VMOD	O
O	O	O	1429	1430	,	,	O	,	O	8	P	O
O	O	O	1431	1438	Western	Western	B-NP	JJ	O	4	NMOD	O
O	O	O	1439	1447	blotting	blotting	I-NP	NN	O	7	NMOD	O
O	O	O	1448	1451	and	and	O	CC	O	7	NMOD	O
O	O	O	1452	1470	immunocytochemical	immunocytochemical	B-NP	JJ	O	7	NMOD	O
O	O	O	1471	1482	experiments	experiment	I-NP	NNS	O	8	SUB	O
O	O	O	1483	1492	indicated	indicate	B-VP	VBD	O	0	ROOT	O
O	O	O	1493	1497	that	that	B-SBAR	IN	O	8	VMOD	O
O	O	O	1498	1502	PDTC	PDTC	B-NP	NN	O	11	SUB	O
O	O	O	1503	1511	promoted	promote	B-VP	VBD	O	9	SBAR	O
O	O	O	1512	1513	a	a	B-NP	DT	O	16	NMOD	O
O	O	O	1514	1523	transient	transient	I-NP	JJ	O	16	NMOD	O
O	O	O	1524	1527	and	and	I-NP	CC	O	13	AMOD	O
O	O	O	1528	1533	rapid	rapid	I-NP	JJ	O	13	AMOD	O
O	O	O	1534	1543	shuttling	shuttling	I-NP	NN	O	11	OBJ	O
O	O	O	1544	1546	of	of	B-PP	IN	O	16	NMOD	O
T7	B-Protein	B-Protein	1547	1552	NFATp	NFATp	B-NP	NN	B-protein	20	NMOD	B-protein
O	O	O	1553	1556	and	and	I-NP	CC	O	20	NMOD	O
O	O	O	1557	1562	NFATc	NFATc	I-NP	NN	B-protein	17	PMOD	B-protein
O	O	O	1562	1563	,	,	O	,	O	11	P	O
O	O	O	1564	1571	leading	lead	B-VP	VBG	O	11	VMOD	O
O	O	O	1572	1574	to	to	B-PP	TO	O	22	VMOD	O
O	O	O	1575	1580	their	their	B-NP	PRP$	O	26	NMOD	O
O	O	O	1581	1592	accelerated	accelerate	I-NP	VBN	O	26	NMOD	O
O	O	O	1593	1599	export	export	I-NP	NN	O	23	PMOD	O
O	O	O	1600	1604	from	from	B-PP	IN	O	26	NMOD	O
O	O	O	1605	1608	the	the	B-NP	DT	O	29	NMOD	O
O	O	O	1609	1616	nucleus	nucleus	I-NP	NN	O	27	PMOD	O
O	O	O	1617	1619	of	of	B-PP	IN	O	29	NMOD	O
O	O	O	1620	1629	activated	activate	B-NP	VBN	B-cell_type	33	NMOD	B-cell_type
O	O	O	1630	1631	T	T	I-NP	NN	I-cell_type	33	NMOD	I-cell_type
O	O	O	1632	1637	cells	cell	I-NP	NNS	I-cell_type	30	PMOD	I-cell_type
O	O	O	1637	1638	.	.	O	.	O	8	P	O

O	O	O	1639	1641	We	We	B-NP	PRP	O	2	SUB	O
O	O	O	1642	1649	propose	propose	B-VP	VBP	O	0	ROOT	O
O	O	O	1650	1654	that	that	B-SBAR	IN	O	2	VMOD	O
O	O	O	1655	1658	the	the	B-NP	DT	O	5	NMOD	O
O	O	O	1659	1669	activation	activation	I-NP	NN	O	12	SUB	O
O	O	O	1670	1672	of	of	B-PP	IN	O	5	NMOD	O
O	O	O	1673	1675	an	an	B-NP	DT	O	9	NMOD	O
O	O	O	1676	1680	NFAT	NFAT	I-NP	NN	B-protein	9	NMOD	B-protein
O	O	O	1681	1687	kinase	kinase	I-NP	NN	I-protein	6	PMOD	I-protein
O	O	O	1688	1690	by	by	B-PP	IN	O	5	NMOD	O
O	O	O	1691	1695	PDTC	PDTC	B-NP	NN	O	10	PMOD	O
O	O	O	1696	1701	could	could	B-VP	MD	O	3	SBAR	O
O	O	O	1702	1704	be	be	I-VP	VB	O	12	VC	O
O	O	O	1705	1716	responsible	responsible	B-ADJP	JJ	O	13	PRD	O
O	O	O	1717	1720	for	for	B-PP	IN	O	14	AMOD	O
O	O	O	1721	1724	the	the	B-NP	DT	O	18	NMOD	O
O	O	O	1725	1730	rapid	rapid	I-NP	JJ	O	18	NMOD	O
O	O	O	1731	1740	shuttling	shuttling	I-NP	NN	O	15	PMOD	O
O	O	O	1741	1743	of	of	B-PP	IN	O	18	NMOD	O
O	O	O	1744	1747	the	the	B-NP	DT	O	21	NMOD	O
O	O	O	1748	1752	NFAT	NFAT	I-NP	NN	B-protein	19	PMOD	B-protein
O	O	O	1752	1753	,	,	O	,	O	12	P	O
O	O	O	1754	1763	therefore	therefore	B-ADVP	RB	O	25	VMOD	O
O	O	O	1764	1775	transiently	transiently	B-VP	RB	O	25	VMOD	O
O	O	O	1776	1786	converting	convert	I-VP	VBG	O	12	VMOD	O
O	O	O	1787	1790	the	the	B-NP	DT	O	28	NMOD	O
O	O	O	1791	1800	sustained	sustained	I-NP	JJ	O	28	NMOD	O
O	O	O	1801	1816	transactivation	transactivation	I-NP	NN	O	25	OBJ	O
O	O	O	1817	1819	of	of	B-PP	IN	O	28	NMOD	O
O	O	O	1820	1824	this	this	B-NP	DT	O	32	NMOD	O
O	O	O	1825	1838	transcription	transcription	I-NP	NN	B-protein	32	NMOD	B-protein
O	O	O	1839	1845	factor	factor	I-NP	NN	I-protein	29	PMOD	I-protein
O	O	O	1846	1850	that	that	B-NP	WDT	O	28	NMOD	O
O	O	O	1851	1857	occurs	occur	B-VP	VBZ	O	33	SBAR	O
O	O	O	1858	1864	during	during	B-PP	IN	O	34	VMOD	O
O	O	O	1865	1875	lymphocyte	lymphocyte	B-NP	NN	O	37	NMOD	O
O	O	O	1876	1886	activation	activation	I-NP	NN	O	35	PMOD	O
O	O	O	1886	1887	,	,	O	,	O	2	P	O
O	O	O	1888	1891	and	and	O	CC	O	2	VMOD	O
O	O	O	1892	1896	show	show	B-VP	VBP	O	2	VMOD	O
O	O	O	1897	1901	that	that	B-SBAR	IN	O	40	VMOD	O
T8	B-Protein	B-Protein	1902	1903	c	c	B-NP	NN	O	48	NMOD	O
T8	I-Protein	I-Protein	1903	1904	-	-	O	HYPH	O	48	NMOD	O
T8	I-Protein	I-Protein	1904	1907	Jun	Jun	B-NP	NN	B-protein	45	NMOD	B-protein
T8	I-Protein	I-Protein	1908	1911	NH2	NH2	I-NP	NN	B-protein	48	NMOD	B-protein
T8	I-Protein	I-Protein	1911	1912	-	-	B-NP	HYPH	O	48	NMOD	O
T8	I-Protein	I-Protein	1912	1920	terminal	terminal	I-NP	JJ	O	48	NMOD	O
T8	I-Protein	I-Protein	1921	1927	kinase	kinase	I-NP	NN	O	52	SUB	O
O	O	O	1928	1929	(	(	O	(	O	51	DEP	O
T9	B-Protein	B-Protein	1929	1932	JNK	JNK	B-NP	NN	B-protein	51	DEP	B-protein
O	O	O	1932	1933	)	)	O	)	O	48	NMOD	O
O	O	O	1934	1937	can	can	B-VP	MD	O	41	SBAR	O
O	O	O	1938	1941	act	act	I-VP	VB	O	52	VC	O
O	O	O	1942	1944	by	by	B-PP	IN	O	53	VMOD	O
O	O	O	1945	1953	directly	directly	B-VP	RB	O	56	VMOD	O
O	O	O	1954	1969	phosphorylating	phosphorylate	I-VP	VBG	O	54	PMOD	O
T10	B-Protein	B-Protein	1970	1975	NFATp	NFATp	B-NP	NN	B-protein	56	OBJ	B-protein
O	O	O	1975	1976	.	.	O	.	O	2	P	O

O	O	O	1977	1979	In	In	B-PP	IN	O	14	VMOD	O
O	O	O	1980	1988	addition	addition	B-NP	NN	O	1	PMOD	O
O	O	O	1988	1989	,	,	O	,	O	14	P	O
O	O	O	1990	1993	the	the	B-NP	DT	O	7	NMOD	O
O	O	O	1994	2002	combined	combined	I-NP	JJ	O	7	NMOD	O
O	O	O	2003	2013	inhibitory	inhibitory	I-NP	JJ	O	7	NMOD	O
O	O	O	2014	2021	effects	effect	I-NP	NNS	O	14	SUB	O
O	O	O	2022	2024	on	on	B-PP	IN	O	7	NMOD	O
O	O	O	2025	2029	NFAT	NFAT	B-NP	NN	B-protein	13	NMOD	B-protein
O	O	O	2030	2033	and	and	I-NP	CC	O	13	NMOD	O
T20	B-Entity	B-Entity	2034	2036	NF	NF	I-NP	NN	B-protein	13	NMOD	B-protein
T20	I-Entity	I-Entity	2036	2037	-	-	O	HYPH	I-protein	13	NMOD	I-protein
T20	I-Entity	I-Entity	2037	2039	KB	KB	B-NP	NN	I-protein	8	PMOD	I-protein
O	O	O	2040	2047	support	support	B-VP	VBP	O	0	ROOT	O
O	O	O	2048	2049	a	a	B-NP	DT	O	17	NMOD	O
O	O	O	2050	2059	potential	potential	I-NP	JJ	O	17	NMOD	O
O	O	O	2060	2063	use	use	I-NP	NN	O	14	OBJ	O
O	O	O	2064	2066	of	of	B-PP	IN	O	17	NMOD	O
O	O	O	2067	2071	DTCs	DTC	B-NP	NNS	O	18	PMOD	O
O	O	O	2072	2074	as	as	B-PP	IN	O	17	NMOD	O
O	O	O	2075	2093	immunosuppressants	immunosuppressant	B-NP	NNS	O	20	PMOD	O
O	O	O	2093	2094	.	.	O	.	O	14	P	O
